Episurf — Regulatory Filings 2016

Jan 25, 2016

Company Announcement January 25, 2016

Episurf Medical announces that 100 account milestone has been reached

In line with a 2015 stated goal, Episurf Medical announces that the milestone of 100 accounts approved and connected to the company's proprietary μifidelity™ platform has been reached.

"I am delighted with this achievement especially considering that we have tightened the inclusion criteria for new accounts to ensure that surgeons can begin doing Episealer® procedures immediately, thereby driving account productivity. This performance indicates our direct sales strategy across the major European geographies is working and demonstrates an acceptance amongst surgeons to address the treatment gap between biologics and arthroplasty with a patient specific Episealer® implant", says Rosemary Cunningham Thomas, CEO of Episurf Medical.

During 2016 Episurf Medical will continue to enlarge and strengthen its sales presence via an active recruitment process in Germany and the UK.

"I am confident that Episurf Medical's expanding European footprint combined with growing patient demand for innovative cartilage treatments will drive accelerated surgical adoption of the Episealer® implant technology in 2016 and beyond. With five patient specific products in the portfolio including its first digital product, Epioscopy™, key sales managers in our main markets and a growing body of clinical evidence, Episurf Medical is well positioned to compete on a global scale in the years to come," says Rosemary Cunningham Thomas.

For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical Tel: +46 (0) 70-7655892 Tel: +44 (0) 7803-753603 rosemary@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system will enable implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.

Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.